Lake Street analyst Brooks O’Neil says there are “certainly at least two ways to look at Harrow now,” noting that pessimists do not trust CEO Mark Baum and do not believe 2023 was transformative for Harrow. However, those who see the glass half full, including the firm, which is “definitely in this camp,” recognize that Harrow is still a work in progress, but see progress with IHEEZO and VEVYE as “major green shoots blooming,” the analyst tells investors. Following the company’s Q4 report and guidance, the firm affirms its Buy rating and $20 price target on Harrow shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health says CMS notification ‘very important development for IHEEZO’
- Harrow Health backs 2024 revenue guidance of at least $180M, consensus $184.91M
- Harrow Health reports Q4 core EPS (20c), consensus (4c)
- Harrow Health Inc Unveils Investor Presentation Update
- Options Volatility and Implied Earnings Moves Today, March 19, 2024